Literature DB >> 8298809

Evidence for heterogeneity of endothelin receptor distribution in human coronary artery.

T Godfraind1.   

Abstract

1. The receptors mediating endothelin-evoked contraction of human coronary artery have been investigated in isolated segments of the left anterior descending coronary artery (LAD). 2. Endothelin-1 (ET-1) was 10 times more potent in distal than in proximal segments but the potency ratio between ET-1 and ET-3 (endothelin-3) was similar and close to 100 in any segment of the artery. 3. BQ-123, an ETA receptor antagonist, competitively antagonized the response to ET-1 of distal segments (pA2 equal to 7.47). In the proximal segments, part of the contractile response was BQ123 sensitive, but the antagonism was non-competitive. In both groups of segments, the response to ET-3 could be completely blocked by BQ-123. 4. These observations indicate that ETA receptors mediate the contractile response to ET-1 in distal, pre-resistant coronary arteries, but that other ET receptors are also involved in the contractile response of proximal segments.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298809      PMCID: PMC2175790          DOI: 10.1111/j.1476-5381.1993.tb13942.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor.

Authors:  T Sakurai; M Yanagisawa; Y Takuwa; H Miyazaki; S Kimura; K Goto; T Masaki
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.

Authors:  M J Mulvany; W Halpern
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

3.  Role of endothelium in the contractile response of rat aorta to alpha-adrenoceptor agonists.

Authors:  T Godfraind; C Egleme; I Al Osachie
Journal:  Clin Sci (Lond)       Date:  1985       Impact factor: 6.124

4.  Enhanced responsiveness of rat isolated aorta to clonidine after removal of the endothelial cells.

Authors:  C Eglème; T Godfraind; R C Miller
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

5.  Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries.

Authors:  A H Chester; G S O'Neil; S Moncada; S Tadjkarimi; M H Yacoub
Journal:  Lancet       Date:  1990-10-13       Impact factor: 79.321

6.  Endothelin-1 induces prostacyclin release from bovine aortic endothelial cells.

Authors:  J G Filep; B Battistini; Y P Côté; A R Beaudoin; P Sirois
Journal:  Biochem Biophys Res Commun       Date:  1991-05-31       Impact factor: 3.575

7.  Endothelin depolarizes myocytes from porcine coronary and human mesenteric arteries through a Ca-activated chloride current.

Authors:  U Klöckner; G Isenberg
Journal:  Pflugers Arch       Date:  1991-03       Impact factor: 3.657

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery.

Authors:  K B Costello; D J Stewart; R Baffour
Journal:  Eur J Pharmacol       Date:  1990-09-21       Impact factor: 4.432

10.  Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle.

Authors:  T Godfraind; A Kaba
Journal:  Br J Pharmacol       Date:  1969-07       Impact factor: 8.739

View more
  15 in total

Review 1.  Calcium antagonists and endothelial function: focus on nitric oxide and endothelin.

Authors:  T Godfraind; S Salomone
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development.

Authors:  Anthony J Donato; Lisa A Lesniewski; Deborah Stuart; Ashley E Walker; Grant Henson; Lise Sorensen; Dean Li; Donald E Kohan
Journal:  Life Sci       Date:  2014-01-08       Impact factor: 5.037

3.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults.

Authors:  Brian L Stauffer; Christian M Westby; Jared J Greiner; Gary P Van Guilder; Christopher A Desouza
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-25       Impact factor: 3.619

5.  Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

6.  Endothelin receptors in human coronary artery and aorta.

Authors:  C R Bacon; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

7.  A selective endothelin ETA antagonist, BQ-123, inhibits 125I-endothelin-1 (125I-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells.

Authors:  N Kitagawa; K Tsutsumi; M Niwa; S Yamaga; T Anda; H Khalid; A Himeno; K Taniyama; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1994-04       Impact factor: 5.046

8.  Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.

Authors:  J J Maguire; R E Kuc; G O'Reilly; A P Davenport
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

9.  Different endothelin receptors involved in endothelin-1- and sarafotoxin S6B-induced contractions of the human isolated coronary artery.

Authors:  W A Bax; Z Aghai; C L van Tricht; C Wassenaar; P R Saxena
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

10.  Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.

Authors:  J J Maguire; R E Kuc; B A Rous; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.